Document:

EX-10.10

 Exhibit 10.10 
 VITAL THERAPIES, INC. 
 Non-Employee Director Compensation Policy

  

	1.	Annual Retainer. $30,000, paid quarterly at the beginning of each quarter, for up to 4 in-person meetings per year and a reasonable amount of phone discussions.
Retainers for partial quarters of service shall be pro-rated to reflect the number of days served by any director during any quarter. 

  

	2.	Expense Reimbursement. Reasonable expenses to attend Board and Committee meetings and to otherwise attend to Company business. 

 

	3.	Board Fees. $2,500 per meeting in excess of 4 per year, plus $500 for each phone meeting of the Board or committee for which minutes are kept.

  

	4.	Annual Board Committee Payment. 

  

	 	a.	Audit Committee: Each member: $7,500; Chairman: additional $7,500 (total of $15,000); paid quarterly at the beginning of each quarter and pro-rated for partial quarters
of service. 

  

	 	b.	Other Committees: Each member: $5,000; Chairman: additional $5,000 (total of $10,000); paid quarterly at the beginning of each quarter and pro-rated for partial
quarters of service. 

  

	5.	Stock options. Initial grant of 50,175 non-qualified common stock options (or such other amount as the Board may determine) at a strike price not less than fair
market value of a share of the Company’s stock on the date of grant to be determined by the Board, vesting in equal monthly portions over 48 months. Equity awards granted prior to a stock split or similar event will be subject to similar
adjustment pursuant to the Company’s 2013 Stock Option Plan. 

  

	6.	Exclusions. The Co-Chairmen and employees are excluded from all the Board compensation. 

 

	7.	Amendment or Termination. The Board may amend or terminate this policy at any time.EX-4.5

 Exhibit 4.5 
  

	
	

 NAVIGATOR HOLDINGS LTD. INCORPORATED UNDER THE MARSHALL ISLANDS BUSINESS CORPORATIONS ACT 
COMMON SHARES SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP Y62132 I0 8 FULLY PAID AND NON-ASSESSABLE COMMON SHARES, PAR VALUE $.01, OF Navigator Holdings Ltd. (hereinafter called the
“Company”) transferable on the books of the Company by the Registered Holder hereof in person or by duly authorized attorney upon surrender of this Certificate properly endorsed. This Certificate and the shares represented hereby are
issued and shall be held subject to all the provisions of the Bylaws and Articles of Incorporation and amendments thereto of the Company. This Certificate is not valid unless countersigned and registered by the Transfer Agent and Registrar. Witness
the facsimile signatures of the duly authorized officers of the Company. Dated: CHIEF EXECUTIVE OFFICER CHIEF FINANCIAL OFFICER AND SECRETARY AMERICAN BANK NOTH COMPANY. Countersigned and registered American stock transfer & trust company, llc
(broollyn, NY) TRANSFER AGENT AND REGISTRAR AUTHORIZED SIGNATURE 

 

 
 This Certificate also evidences and entitles the holder hereof to certain Rights as set forth in a Rights Agreement between Navigator
Holdings Ltd. and American Stock Transfer and Trust Company, LLC, dated as of May 30, 2012 (as it may be amended from time to time, the “Rights Agreement”), the terms of which are hereby incorporated herein by reference and a copy of which
is on file at the principal executive offices of Navigator Holdings Ltd. The Rights are not exercisable prior to the occurrence of certain events specified in the Rights Agreement. Linder certain circumstances, as set forth in the Rights Agreement,
such Rights may be redeemed, may be exchanged, may expire, may be amended or may be evidenced by separate certificates and no longer be evidenced by this Certificate. Navigator Holdings Ltd. will mail to the holder of this Certificate a copy of the
Rights Agreement, as in effect on the date of mailing, without charge promptly after receipt of a written request therefor. Under certain circumstances as set forth in the Rights Agreement, Rights that are or were beneficially owned by an Acquiring
Person or any Affiliate or Associate of an Acquiring Person (as such terms are defined in the Rights Agreement) may become null and void. The following abbreviations, when used in the inscription on the face of this certificate, shall be construed
as though they were written out in full according to applicable laws or regulations: TEN COM — as tenants in common JT TEN — as joint tenants with right of survivorship and not as tenants in common UNIF GIFT MIN ACT — Custodian
(Clist) (Minor) under Uniform Gifts to Minors Act (State) Additional abbreviations may also be used though not in the above list.For Value Received, PLEASE INSERT SOCIAL SECURITY OR OTHER IDENTIFYING NUMBER OF ASSIGNEE (PLEASE PRINT OR TYPEWRITE
NAME AND ADDRESS, INCLUDING ZIP CODE, OF ASSIGNEE) of the Common Shares represented by the within Certificate, and do hereby irrevocably constitute and appoint Attorney to transfer the said stock on the books of the within named Company with full
power of substitution in the premises. Dated THE SIGNATURE TO THIS ASSIGNMENT MUST CORRESPOND WITH THE NAME AS WRITTEN UPON THE FACE OF NOTICE: THE CERTIFICATE IN EVERY PARTICULAR, WITHOUT ALTERATION OR ENLARGEMENT OR ANY CHANGE WHATEVER.
Signature(s) Guaranteed: THE SIGNATURE(S) MUST BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM), PURSUANT
TO S.E.C. RULE 17Ad-15.EX-4.1

 Exhibit 4.1 

P19- 
 Series 19 Preferred Stock

 CELL THERAPEUTICS, INC. 

A Washington Corporation 

THIS CERTIFIES THAT
*                                * is the record holder of *
                    (            ) * shares of Series 19 Preferred Stock
of Cell Therapeutics, Inc. (the “Corporation”) transferable only on the share register of the Corporation by the holder, in person or by such holder’s duly authorized attorney, upon surrender of this certificate properly
endorsed or assigned. 
 This certificate and the shares represented hereby shall be held subject to all of the provisions of the Amended
and Restated Articles of Incorporation, as amended, and the Second Amended and Restated Bylaws of the Corporation, and any amendments thereto, a copy of each of which is on file at the office of the Corporation and made a part hereof as fully as
though the provisions of said Amended and Restated Articles of Incorporation and Second Amended and Restated Bylaws were imprinted in full on this Certificate, to all of which the holder of this Certificate, by acceptance hereof, assents and agrees
to be bound. 
 The shares represented by this Certificate are convertible into shares of Common Stock as set forth in the Amended and
Restated Articles of Incorporation of the Corporation. 
 The Corporation will furnish without charge to each shareholder who so requests,
the powers, designations, preferences and relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences or rights. 

IN WITNESS WHEREOF, the Corporation has caused this Certificate to be signed by its duly authorized officers this
             day of November, 2013. 
  

							
	  
	 		  	  
	  	
	James A. Bianco, M.D., 	 		  	Louis A. Bianco,	  	
	President and Chief Executive Officer	 		  	Executive Vice President, Finance and Administration	  	

 FOR VALUE RECEIVED, THE UNDERSIGNED HEREBY SELLS, ASSIGNS AND TRANSFERS UNTO
                                         
                   
                                         
                    SHARES REPRESENTED BY THE WITHIN CERTIFICATE AND DOES HEREBY IRREVOCABLY CONSTITUTE AND APPOINT
                                 ATTORNEY TO TRANSFER THE SAID SHARES ON THE SHARE
REGISTER OF THE WITHIN NAMED CORPORATION WITH FULL POWER OF SUBSTITUTION IN THE PREMISES. 
 DATED
                     
  

	
	  

(Signature)

 NOTICE: THE SIGNATURE ON THIS ASSIGNMENT MUST CORRESPOND WITH THE NAME AS WRITTEN UPON THE FACE OF THIS CERTIFICATE, IN
EVERY PARTICULAR, WITHOUT ALTERATION OR ENLARGEMENT, OR ANY CHANGE WHATEVER. 
 THE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL SATISFACTORY TO THE
COMPANY THAT REGISTRATION IS NOT REQUIRED UNDER SUCH ACT OR UNLESS SOLD PURSUANT TO RULE 144 UNDER SUCH ACT.EX-10.1

 Exhibit 10.1 

REGISTRATION RIGHTS AGREEMENT 

This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made as of November 14, 2013, by and among (i) Cell
Therapeutics, Inc., a Washington corporation (the “Company”), (ii) Baxter Healthcare SA, a company organized under the laws of Switzerland (the “Initial Holder”), and (iii) each person or entity that
subsequently becomes a party to this Agreement pursuant to, and in accordance with, the provisions of Section 12 hereof (collectively, the “Holder Permitted Transferees,” and each individually, a “Holder
Permitted Transferee”). 
 WHEREAS, pursuant to the terms and conditions set forth in that certain Development, Commercialization
and License Agreement, dated as of November 14, 2013, between the Company and the Initial Holder (the “DCLA”), the Initial Holder has agreed to purchase from the Company, and the Company has agreed to issue and sell to Baxter,
shares of the Company’s Series 19 Preferred Stock and/or shares of the Company’s common stock, all upon the terms and conditions set forth in the DCLA. 

WHEREAS, the terms of the DCLA provide for the Company and the Initial Holder to execute and deliver this Agreement. 

NOW, THEREFORE, in consideration of the premises and mutual covenants contained herein, the parties hereto hereby agree as follows: 

1. Definitions. The following terms shall have the meanings provided therefor below or elsewhere in this Agreement as described below: 

“Agreement” has the meaning set forth in the Preamble. 

“Board” means the board of directors of the Company. 

“Business Day” means any day other than a Saturday, a Sunday or a day on which banks in New York are authorized or obligated
by law or executive order to close. 
 “Company” has the meaning set forth in the Preamble. 

“DCLA” has the meaning set forth in the Preamble. 

“Effective Date” has the meaning set forth in the DCLA. 

“Exchange Act” means the Securities Exchange Act of 1934, as amended, and all of the rules and regulations promulgated
thereunder. 
 “Holder Indemnified Person” has the meaning set forth in Section 9.1. 

“Holder Permitted Transferee” and “Holder Permitted Transferees” have the meanings set forth in the
Preamble. 

 “Holders” means, collectively, the Initial Holder and the Holder Permitted
Transferees; provided, however, that the term “Holders” shall not include the Initial Holder or any of the Holder Permitted Transferees if such Holder ceases to own or hold any Registrable Shares. 

“Initial Holder” has the meaning set forth in the Preamble. 

“Loss” has the meaning set forth in Section 9.1. 

“Mandatory Registration Termination Date” has the meaning set forth in Section 3.2. 

“Majority Holders” means, at the relevant time of reference thereto, those Holders holding more than fifty percent
(50%) of the Registrable Shares held by all of the Holders. 
 “Qualifying Holder” has the meaning set forth in
Section 12. 
 “Registrable Shares” means (i) any shares of common stock of the Company issued to the
Initial Holder, (ii) any shares of common stock of the Company issuable upon conversion of any shares of Series 19 Preferred Stock issued to the Initial Holder or (iii) any common stock issued as (or issuable upon the conversion or
exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, such common stock or Series 19 Preferred Stock. For the avoidance of doubt, a security
shall cease to be a Registrable Share once it has been sold in an SEC-registered transaction or pursuant to Rule 144. 

“Registration Statement” has the meaning set forth in Section 3.1. 

“Rule 144” means Rule 144 promulgated under the Securities Act and any successor or substitute rule, law or provision. 

“SEC” means the U.S. Securities and Exchange Commission. 

“Securities Act” means the Securities Act of 1933, as amended, and all of the rules and regulations promulgated thereunder.

 “Suspension Period” has the meaning set forth in Section 11. 

2. Effectiveness. This Agreement shall become effective and legally binding on the Effective Date. 

3. Mandatory Registration. 
 3.1. Within
thirty (30) calendar days after the Effective Date, the Company will prepare and file with the SEC a registration statement on Form S-3, or any other available form if the Company is not eligible to use Form S-3, for the purpose of registering
under the Securities Act all of the Registrable Shares for resale by, and for the account of, the Holders as selling stockholders thereunder (the “Registration Statement”). The Registration Statement shall permit the Holders to
offer and sell, on a delayed or continuous basis pursuant to Rule 415 under the Securities Act, any or all of the Registrable Shares. The Company agrees to use commercially reasonable efforts to cause the Registration Statement to become effective
as soon as practicable 

  
 2 

 
after the filing thereof, and in no event later than the earlier of (i) ninety (90) calendar days following the Effective Date (subject to reasonable extension to the extent necessary
to accommodate a delay resulting from unresolved SEC comments or the need to file financial statements within the time periods prescribed by the SEC) and (ii) the fifth calendar day following the date on which the Company is notified by the SEC
that (a) such Registration Statement will not be reviewed or is no longer subject to further review and comments and that (b) the SEC is willing to declare the Registration Statement effective. The Registration Statement filed pursuant to
this Section 3.1 (and each amendment or supplement thereto, and each request for acceleration of effectiveness thereof) shall be provided to each Holder and its counsel prior to its filing or other submission. 

3.2. The Company shall be required to keep the Registration Statement effective until such date that is the earlier to occur of (i) the
date as of which all of the Holders may sell all of the Registrable Shares to the public without restriction pursuant to Rule 144 (or the successor rule thereto) promulgated under the Securities Act, and (ii) the date when all of the
Registrable Shares registered thereunder shall have been sold pursuant to the Registration Statement or Rule 144 (such date is referred to herein as the “Mandatory Registration Termination Date”). Thereafter, the Company shall be
entitled to withdraw the Registration Statement and the Holders shall have no further right to offer or sell any of the Registrable Shares pursuant to the Registration Statement (or any prospectus relating thereto). The Company shall not be required
to register the offer and sale of the Registrable Shares pursuant to the Registration Statement in an underwritten offering. 
 3.3. The
Company shall not, and shall not agree to (i) allow the holders of any securities of the Company, other than holders of the Registrable Shares, to include any of their securities in the Registration Statement under Section 3.1
hereof or any amendment or supplement thereto without the consent of the Holders or (ii) offer any securities for its own account or the account of others in the Registration Statement under Section 3.1 hereof or any amendment or
supplement thereto without the consent of the Holders, in each such case, subject to, and other than with respect to, any registration obligations of the Company under any agreement entered into prior to the Effective Date; provided,
however, that the Company at all times reserves the right to provide registration rights, pursuant to a separate registration statement, to the holders of any securities of the Company. 

4. Notification of Effectiveness. Company shall notify the Holders by facsimile or e-mail (as provided by Holders) as promptly as practicable, and in
any event, within twenty-four (24) hours, after the Registration Statement is declared effective and shall simultaneously provide the Holders with copies of any related prospectus to be used in connection with the sale or other disposition of
the securities covered thereby. 
 5. Obligations of the Company. In connection with the Company’s obligation under Sections 3 and
4 hereof to file the Registration Statement with the SEC and to use commercially reasonable efforts to cause the Registration Statement to become effective as soon as practicable, the Company shall, as expeditiously as reasonably possible:

 5.1. Prepare and file with the SEC such amendments and supplements to the Registration Statement and the prospectus used in connection
therewith as may be necessary to 

  
 3 

 
comply with the provisions of the Securities Act with respect to the disposition of all Registrable Shares covered by the Registration Statement, and furnish to each Holder and the single firm of
counsel designated by the Holders to the extent requested by such Holder or counsel, without charge, at least one conformed copy of each Registration Statement and each amendment thereto, including financial statements and schedules, all documents
incorporated or deemed to be incorporated therein by reference, and all exhibits (including those previously furnished or incorporated by reference) promptly after the filing of such documents with the SEC; 

5.2. Furnish to the Holders, without charge, such number of copies of a prospectus, including a preliminary prospectus, in conformity with the
requirements of the Securities Act, and such other documents (including, without limitation, prospectus amendments and supplements as are prepared by the Company in accordance with Section 5.1 above) as the Holders may reasonably request
in order to facilitate the disposition of such Holders’ Registrable Shares. The Company hereby consents to the use of such prospectus and each amendment or supplement thereto by each of the selling Holders in connection with the offering and
sale of the Registrable Shares covered by such prospectus and any amendment or supplement thereto. 
 5.3. Notify the Holders as promptly as
reasonably possible, at any time when a prospectus relating to the Registration Statement is required to be delivered under the Securities Act, of the happening of any event as a result of which the prospectus included in or relating to the
Registration Statement contains an untrue statement of a material fact or omits any fact necessary to make the statements therein not misleading; and, thereafter, the Company will promptly prepare (and, when completed, give notice to each Holder) a
supplement or amendment to such prospectus so that, as thereafter delivered to the purchasers of such Registrable Shares, such prospectus will not contain an untrue statement of a material fact or omit to state any fact necessary to make the
statements therein not misleading; upon such notification by the Company, the Holders will not offer or sell Registrable Shares until the Company has notified the Holders that it has prepared a supplement or amendment to such prospectus and
delivered copies of such supplement or amendment to the Holders (it being understood and agreed by the Company that the foregoing clause shall in no way diminish or otherwise impair the Company’s obligation to promptly prepare a prospectus
amendment or supplement as above provided in this Section 5.3 and deliver copies of same as above provided in Section 5.2 hereof); 

5.4. Promptly respond to any and all comments received from the SEC, with a view towards causing the Registration Statement or any amendment
thereto to be declared effective by the SEC as soon as practicable, and file an acceleration request as soon as practicable, but no later than five (5) Business Days, following the resolution or clearance of all SEC comments or, if applicable,
notification by the SEC that any such Registration Statement or any amendment thereto will not be subject to review; 
 5.5. Use
commercially reasonable efforts to register and qualify the Registrable Shares covered by the Registration Statement under such other securities or Blue Sky laws of such states where such registration and/or qualification is required as shall be
reasonably requested by a Holder, provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a general consent to service of process in any such states or jurisdictions, and
provided further that (notwithstanding anything in this Agreement to the contrary with respect to the bearing of expenses) if any jurisdiction in which 

  
 4 

 
any of such Registrable Shares shall be qualified shall require that expenses incurred in connection with the qualification therein of any such Registrable Shares be borne by the Holders, then
the Holders shall, to the extent required by such jurisdiction, pay their pro rata share of such qualification expenses; 
 5.6. Subject to
the terms and conditions of this Agreement, use commercially reasonable efforts to (i) prevent the issuance of any stop order or other suspension of effectiveness of a Registration Statement, or the suspension of the qualification of any of the
Registrable Shares for sale in any jurisdiction in the United States, and (ii) if such an order or suspension is issued, obtain the withdrawal of such order or suspension at the earliest practicable moment and notify each holder of Registrable
Shares of the issuance of such order and the resolution thereof or its receipt of notice of the initiation or threat of any proceeding such purpose; 

5.7. Permit a single firm of counsel designated by the Holders to review the Registration Statement and all amendments and supplements thereto
(as well as all requests for acceleration or effectiveness thereof), at Holders’ own cost, a reasonable period of time prior to their filing with the SEC (not less than five (5) Business Days) and use commercially reasonable efforts to
reflect in such documents any comments as such counsel may reasonably propose (so long as such comments are provided to the Company at least (2) Business Days prior to the expected filing date) and will not request acceleration of such
Registration Statement without prior notice to such counsel, provided, however that the Company shall not file the Registration Statement or any amendments or supplements thereto to which the Majority Holders and the counsel designated by the
Holders shall reasonably object in good faith; 
 5.8. Cooperate with the Holders to facilitate the timely preparation and delivery of
certificates representing Registrable Shares to be delivered to a transferee pursuant to the Registration Statement, which certificates shall be free, to the extent permitted by law, of all restrictive legends, and to enable such Registrable Shares
to be in such denominations and registered in such names as any such Holders may request; 
 5.9. Comply with all applicable rules and
regulations of the SEC; 
 5.10. Use commercially reasonable efforts to cause all the Registrable Shares covered by the Registration
Statement to be listed on the NASDAQ National Market, or such other securities exchange on which the Company’s common stock is then listed; and 

5.11. Comply with all requirements of the Financial Industry Regulatory Authority, Inc. with regard to the issuance of the Registrable Shares
and the listing thereof on the NASDAQ National Market, and engage a transfer agent and registrar to maintain the Company’s stock ledger for all Registrable Shares covered by the Registration Statement not later than the effective date of the
Registration Statement. 
 6. Furnish Information. It shall be a condition precedent to the obligations of the Company to take any action pursuant to
this Agreement that the Holders shall furnish to the Company such information regarding them and the securities held by them as the Company shall reasonably request and as shall be required in order to effect any registration by the Company pursuant
to this Agreement. Each Holder shall promptly notify the Company of any changes in the information furnished to the Company. 

  
 5 

 7. Expenses of Registration. All fees and expenses incurred by the Company in connection with the
registration of the Registrable Shares pursuant to this Agreement, including, without limitation, all registration and qualification and filing fees, printing (including, without limitation, expenses of printing certificates for Registrable Shares
and of printing prospectuses if the printing of prospectuses is reasonably requested by the holders of a majority of the Registrable Shares included in the Registration Statement), fees and disbursements of counsel for, or other persons retained by,
the Company, and fees and expenses incident to the performance of or compliance with this Agreement by the Company, shall be borne by the Company. In addition, the Company shall be responsible for all of its internal expenses incurred in connection
with the consummation of the transactions contemplated by this Agreement (including, without limitation, all salaries and expenses of its officers and employees performing legal or accounting duties), the expense of any annual audit and the fees and
expenses incurred in connection with the listing of the Registrable Shares on any securities exchange as required hereunder. Any expenses incurred by a Holder, including, without limitation, fees and disbursements of counsel for such Holder or any
brokerage and other selling commissions and discounts shall be borne by such Holder. 
 8. Delay of Registration. The Holders shall not take any
action with the primary intent to restrain, enjoin or otherwise delay any registration as the result of any controversy which might arise with respect to the interpretation or implementation of this Agreement. In the event such a delay occurs
because of such action, the dates by which the Registration Statement is required to be filed and become effective pursuant to this Agreement shall be extended by the same number of days of such delay. 

9. Indemnification. 
 9.1. The Company
will, notwithstanding any termination of this Agreement, indemnify and hold harmless each Holder, the officers, directors, agents and employees of each of them, each person who controls each Holder within the meaning of the Securities Act or the
Exchange Act, if any, and the officers, directors, agents and employees of each such controlling person (in each case, a “Holder Indemnified Person”), to the fullest extent permitted by applicable law, from and against any loss,
claim, damage, cost (including, without limitation, reasonable costs of preparation and reasonable attorneys’ fees), expenses, or liability (“Loss”), to which such Holder Indemnified Person may become subject under the
Securities Act or otherwise, insofar as such Loss arises out of or is based upon (i) any untrue or alleged untrue statement of any material fact contained in the Registration Statement, in any preliminary prospectus or final prospectus relating
thereto or in any amendments or supplements to the Registration Statement or any such preliminary prospectus or final prospectus, or (ii) the omission or alleged omission to state therein a material fact required to be stated therein, or
necessary to make the statements therein not misleading; provided, however, that the indemnity agreement contained in this Section 9.1 shall not apply to amounts paid in settlement of any such Loss if such settlement is
effected without the consent of the Company (such consent not to be unreasonably withheld, conditioned or delayed), nor shall the Company be liable in any such case for any such Loss to the extent, but only to the extent, that it arises solely out
of or is based 

  
 6 

 
solely upon (1) an untrue statement or alleged untrue statement or omission or alleged omission made in connection with the Registration Statement, any preliminary prospectus or final
prospectus relating thereto or any amendments or supplements to the Registration Statement or any such preliminary prospectus or final prospectus, based upon and in conformity with written information furnished expressly for use in connection with
the Registration Statement or any such preliminary prospectus or final prospectus by a Holder, any underwriter for such Holder or controlling person with respect to such Holder, or (2) any breach by any Holder of this Agreement or the failure
of such Holder to comply with the covenants and agreements contained in this Agreement respecting sales of the Registrable Shares. 
 9.2.
Each Holder will severally and not jointly indemnify and hold harmless the Company, each of its directors, each of its officers who have signed the Registration Statement, each person, if any, who controls the Company within the meaning of the
Securities Act, and all other Holders against any Loss to which the Company or any such director, officer, controlling person, or such other Holder may become subject to, under the Securities Act or otherwise, insofar as such Loss arises solely out
of or is based solely upon any untrue or alleged untrue statement of any material fact contained in the Registration Statement or any preliminary prospectus or final prospectus, relating thereto or in any amendments or supplements to the
Registration Statement or any such preliminary prospectus or final prospectus, or arises out of or is based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements
therein not misleading, in each case to the extent and only to the extent that such untrue statement or alleged untrue statement or omission or alleged omission was made in the Registration Statement, in any preliminary prospectus or final
prospectus relating thereto or in any amendments or supplements to the Registration Statement or any such preliminary prospectus or final prospectus, in reliance upon and in conformity with written information furnished by the Holder expressly for
use in connection with the Registration Statement, or any preliminary prospectus or final prospectus; and provided, further, however, that the indemnity agreement contained in this Section 9.2 shall not apply to
amounts paid in settlement of any such Loss if such settlement is effected without the consent of those Holder(s) against which the request for indemnity is being made. In no event shall the liability of any selling Holder hereunder be greater in
amount than the dollar amount of the net proceeds received by such Holder upon the sale of the Registrable Shares giving rise to such indemnification obligation. 

9.3. Promptly after receipt by an indemnified party under this Section 9 of notice of the commencement of any action, such
indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 9, notify the indemnifying party in writing of the commencement thereof and the indemnifying party shall have the right
to participate in and, to the extent the indemnifying party desires, jointly with any other indemnifying party similarly noticed, to assume at its expense the defense thereof with counsel mutually satisfactory to the indemnifying parties and the
indemnified parties. In the event that the indemnifying party assumes any such defense, the indemnified party may participate in such defense with its own counsel and at its own expense, provided, however, that the counsel for the
indemnifying party shall act as lead counsel in all matters pertaining to such defense or settlement of such claim. The failure to notify an indemnifying party promptly of the commencement of any such action shall not relieve such indemnifying party
of any liability to the indemnified party under this Section 9, except (and only) to the extent the indemnifying party is actually and materially adversely prejudiced in its ability to defend such action. 

  
 7 

 9.4. If the indemnification provided for in this Section 9 is held by a court of
competent jurisdiction to be unavailable to an indemnified party with respect to any Loss referred to therein, then the indemnifying party, in lieu of indemnifying such indemnified party hereunder, shall, to the extent permitted by applicable law,
contribute to the amount paid or payable by such indemnified party as a result of such Loss in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and of the indemnified party on the other in
connection with the statements or omissions that resulted in such Loss as well as any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other
things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent,
knowledge, access to information, and opportunity to correct or prevent such statement or omission. The indemnity and contribution agreements contained in this Agreement are in addition to any liability that the indemnifying parties may have to the
indemnified parties. 
 10. Reports Under The Exchange Act. With a view to making available to the Holders the benefits of Rule 144 and any other
rule or regulation of the SEC that may at any time permit the Holders to sell the Registrable Shares to the public without registration until the Mandatory Registration Termination Date, the Company agrees to use commercially reasonable efforts:
(i) to make and keep public information available as those terms are understood in Rule 144, (ii) to file with the SEC in a timely manner all reports and other documents required to be filed by an issuer of securities registered under the
Securities Act or the Exchange Act, (iii) as long as any Holder owns any Registrable Shares, to furnish in writing upon such Holder’s request a written statement by the Company that it has complied with the reporting requirements of Rule
144 and of the Securities Act and the Exchange Act, and (iv) undertake any additional actions reasonably necessary to maintain the availability of the Registration Statement or the use of Rule 144. 

11. Suspension. Notwithstanding anything in this Agreement to the contrary, if the Company shall furnish to the Holders a certificate signed by the
President or Chief Executive Officer of the Company stating that the Board has made the good faith determination (i) that continued use by the Holders of the Registration Statement for purposes of effecting offers or sales of Registrable Shares
pursuant thereto would require, under the Securities Act, premature disclosure in the Registration Statement (or the prospectus relating thereto) of material, nonpublic information concerning the Company, its business or prospects or any proposed
material transaction involving the Company, (ii) that such premature disclosure would be materially adverse to the Company, its business or prospects or any such proposed material transaction or would make the successful consummation by the
Company of any such material transaction significantly less likely and (iii) that it is therefore essential to suspend the use by the Holders of such Registration Statement (and the prospectus relating thereto) for purposes of effecting offers
or sales of Registrable Shares pursuant thereto, then the right of the Holders to use the Registration Statement (and the prospectus relating thereto) for purposes of effecting offers or sales of Registrable Shares pursuant thereto shall be
suspended for a period (the “Suspension Period”) of not more than forty-five (45) days after delivery by the Company of the 

  
 8 

 
certificate referred to above in this Section 11; provided that the Company shall be entitled to no more than two (2) such Suspension Periods during any twelve (12) month
period. During the Suspension Period, none of the Holders shall offer or sell any Registrable Shares pursuant to or in reliance upon the Registration Statement (or the prospectus relating thereto). The Company shall use commercially reasonable
efforts to terminate any Suspension Period as promptly as practicable. 
 12. Transfer of Registration Rights. None of the rights of any Holder under
this Agreement shall be transferred or assigned to any person unless (i) such person is a Qualifying Holder (as defined below), and (ii) such person agrees to become a party to, and bound by, all of the terms and conditions of, this
Agreement by duly executing and delivering to the Company an Instrument of Adherence in the form attached as Exhibit A hereto. For purposes of this Section 12, the term “Qualifying Holder” shall mean, with respect
to any Holder, (a) any corporation, partnership controlling, controlled by, or under common control with, such Holder or any partner thereof, or (b) any other direct transferee from such Holder of at least 25% of those Registrable Shares
held by such Holder. None of the rights of any Holder under this Agreement shall be transferred or assigned to any Person (including, without limitation, a Qualifying Holder) that acquires Registrable Shares in the event that and to the extent that
such Person is eligible to immediately resell such Registrable Shares pursuant to Rule 144 of the Securities Act or any other exemption from the registration provisions of the Securities Act. After any transfer in accordance with this
Section 12, the rights and obligations of a Holder as to any transferred Registrable Shares shall be the rights and obligations of the Holder Permitted Transferee holding such Registrable Shares. 

13. Confidentiality of Records. Each Holder agrees not to disclose any material non-public information provided by the Company in connection with a
registration (including, without limitation, the contemplated filing and timing of filing of a Registration Statement). 
 14. Entire Agreement.
This Agreement constitutes and contains the entire agreement and understanding of the parties with respect to the subject matter hereof, and it also supersedes any and all prior negotiations, correspondence, agreements or understandings with
respect to the subject matter hereof. 
 15. Miscellaneous. 

15.1. This Agreement may not be amended, modified or terminated, and no rights or provisions may be waived, except with the written consent of
the Majority Holders and the Company. 
 15.2. This Agreement shall be governed by and construed and enforced in accordance with the laws of
the State of New York, and shall be binding upon and inure to the benefit of the parties hereto and their respective heirs, personal representatives, successors or assigns, provided that the terms and conditions of Section 12 hereof are
satisfied. 
 15.3. This Agreement shall be binding upon and inure to the benefit of any transferee of any of the Registrable Shares
provided that the terms and conditions of Section 12 hereof are satisfied. Notwithstanding anything in this Agreement to the contrary, if at any time any Holder shall cease to own any Registrable Shares, all of such Holder’s rights
under this Agreement shall immediately terminate. 

  
 9 

 15.4. All notices and communications hereunder shall be deemed to have been duly given and made
if in writing and if served by personal delivery upon the party for whom it is intended or delivered by registered or certified mail, return receipt requested, or if sent by facsimile or email, provided that the facsimile or email is promptly
confirmed by telephone confirmation thereof, to the person at the address set forth below, or such other address as may be designated in writing hereafter, in the same manner, by such person: 

If to the Company: 
 Cell
Therapeutics, Inc. 
 3101 Western Avenue, Suite 600 

Seattle, Washington 98121 

Telephone: (206) 272-4000 

Facsimile: (206) 272-4302 

Email: 
 Attention: James A.
Bianco, M.D., Chief Executive Officer 
 with copies to: 

O’Melveny & Myers LLP 

Two Embarcadero Center 
 San
Francisco, CA 94111-3823 
 Telephone: (415) 984-8700 

Facsimile: (415) 984-8701 

Email: 
 Attention: C. Brophy
Christensen, Esq. and Eric Sibbitt, Esq. 
 and 

CTI Legal Affairs 
 Attention:
Lisa Luebeck, Director, Legal Corporate Development & Securities 
 If to the Initial Holder: 

Baxter Healthcare SA 
 Postfach

 8010 Zurich, Switzerland 

Telephone: +41 44 878 60 00 

Facsimile: +41 44 878 63 50 

Attention: Legal Department 

  
 10 

 with a copy to counsel, provided that such copy shall not constitute legal notice to the Initial
Holder: 
 Baxter Healthcare Corporation 

One Baxter Parkway 
 Deerfield,
Illinois 60015 
 Telephone: (224) 948-3440 

Facsimile: (224) 948-2590 

Email: 
 Attention: General
Counsel 
 15.5. Any person may change the address to which correspondence to it is to be addressed by notification as provided for herein.

 15.6. The parties acknowledge and agree that in the event of any breach of this Agreement, remedies at law may be inadequate, and each of
the parties hereto shall be entitled to seek specific performance of the obligations of the other parties hereto and such appropriate injunctive relief as may be granted by a court of competent jurisdiction, without the necessity of showing economic
loss and without any bond or other security being required. 
 15.7. This Agreement may be executed in a number of counterparts, including
by electronic transmission, any of which together shall for all purposes constitute one Agreement, binding on all the parties hereto notwithstanding that all such parties have not signed the same counterpart. 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 11 

 IN WITNESS WHEREOF, each Holder and the Company have caused their respective signature pages to
this Registration Rights Agreement to be duly executed as of the day and year first above written. 
  

	
	CELL THERAPEUTICS, INC.
	
	 /s/ James A. Bianco

	Name: James A. Bianco, M.D.
	Title:   President and Chief Executive Officer

 [SIGNATURE PAGE TO REGISTRATION
RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, each Holder and the Company have caused their respective signature pages to
this Registration Rights Agreement to be duly executed as of the day and year first above written. 
  

	
	BAXTER HEALTHCARE SA
	
	 /s/ Pier Pollini

	Name: Pier Pollini
	Title:   Senior Director Supply Chain
	
	 /s/ Philippe Francois

	Name: Philippe Francois
	Title:   Vice President Supply Chain EMEA

 [SIGNATURE PAGE TO REGISTRATION
RIGHTS AGREEMENT] 

 EXHIBIT A 

Instrument of Adherence 

Reference is hereby made to that certain Registration Rights Agreement, dated as of November 14, 2013, among Cell Therapeutics, Inc., a
Washington corporation (the “Company”), the Initial Holder and the Holder Permitted Transferees, as amended and in effect from time to time (the “Registration Rights Agreement”). Capitalized terms used herein
without definition shall have the respective meanings ascribed thereto in the Registration Rights Agreement. 
 The undersigned, in order to
become the owner or holder of [            ] shares of Series 19 Preferred Stock (the “Preferred Stock”) or shares of common stock of the Company issuable upon conversion
of the Preferred Stock (collectively, “Subject Securities”), of the Company, hereby agrees that, from and after the date hereof, the undersigned has become a party to the Registration Rights Agreement in the capacity of a Holder
Permitted Transferee, and is entitled to all of the benefits under, and is subject to all of the obligations, restrictions and limitations set forth in, the Registration Rights Agreement that are applicable to Holder Permitted Transferees. The
notice information for purposes of the Registration Rights Agreement is provided below. This Instrument of Adherence shall take effect and shall become a part of the Registration Rights Agreement immediately upon execution. 

Executed as of the date set forth below under the laws of New York. 

 

			
	Signature:	 	  

		 	      Name:
		 	      Title:
		 	      Telephone:
		 	      Facsimile:
		 	      Email:
		 	      Attention:

  

			
	Accepted:
	
	CELL THERAPEUTICS, INC.
		
	By:	 	  

		 	Name:
		 	Title:

 Date:
                    , 2013 

  
 A-1 

[EXHIBIT A TO REGISTRATION RIGHTS AGREEMENT]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}]]